SHINE Technologies has secured Centralized Marketing Authorization in Europe for Ilumira (non-carrier-added lutetium-177), granting the Wisconsin-based fusion company the regulatory clearance needed to sell its Lu-177 radioisotope into the European Union. The authorization positions SHINE as a new entrant in the EU supply chain for targeted radioligand therapy, a segment that has grown substantially following the approvals of finished Lu-177-based therapeutics in recent years.
Ilumira is not a finished drug product and is not intended for direct patient administration. Rather, it is a radiopharmaceutical precursor — a highly purified form of lutetium-177 chloride that must be radiolabelled onto authorized carrier molecules before clinical use. Its authorized indication mirrors the language applied to existing EU-approved Lu-177 precursors: supply to manufacturers producing specifically developed and authorized radioligand therapies.
The product is manufactured at SHINE’s Cassiopeia facility in Janesville, Wisconsin, making it one of the few US-based sources of n.c.a. Lu-177 approved for the European market. SHINE describes the authorization as part of a broader strategy to build an integrated nuclear medicine platform spanning both diagnostic and therapeutic radioisotopes.
The biological rationale for non-carrier-added Lu-177 centers on isotopic purity. In n.c.a. production, lutetium-177 is generated without stable lutetium isotope contamination, which can compete with the therapeutic isotope for binding sites on the carrier molecule and reduce the effective delivered dose. Higher specific activity in n.c.a. Lu-177 is therefore considered advantageous for radiolabelling efficiency, particularly for targeting ligands where receptor density is limited.
SHINE’s entry into the EU market places it in direct competition with two established suppliers. ITM Radiopharma’s EndolucinBeta, approved by the EMA in August 2016, has been the dominant n.c.a. Lu-177 precursor in Europe for nearly a decade. Eckert & Ziegler’s Theralugand received authorization more recently, in November 2024, signaling that regulators and the market have accommodated multiple suppliers as demand from finished-product manufacturers has grown. Ilumira joins this field as a US-manufactured alternative, which may carry supply chain diversification value for European radioligand therapy developers seeking to reduce dependence on European isotope production infrastructure.
SHINE’s broader ambitions extend beyond Lu-177 supply. The company, which originated from fusion neutron technology developed at Phoenix Nuclear Labs before a 2021 merger consolidated both entities under the SHINE Technologies name, has positioned isotope commercialization as the near-term revenue base funding longer-term fusion energy development — an unusual corporate structure that distinguishes it from conventional radiopharmaceutical suppliers.